# TetraLogic Pharmaceuticals Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tetralogic-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Malvern, US
- Website: www.tetralogicpharma.com
- Total disclosed funding: $70M
- Latest round: Series C (May 24, 2011)
- Investors on record: 12

## About

TetraLogic Pharmaceuticals Corporation is a biopharmaceutical company focused on discovering and developing innovative therapies to treat cancer and other serious diseases through targeted approaches.Founded in 2001 and headquartered in Malvern, US, TetraLogic Pharmaceuticals is dedicated to advancing therapeutic solutions for cancer treatment. The company has executed 9 notable deals, with its most recent funding event being an IPO in December 2013, raising USD 50 mn by selling 7.2 million shares at a price of USD 7 each. TetraLogic Pharmaceuticals specializes in biopharmaceutical innovations targeting cancer treatments. Their primary focus lies in developing novel therapies that leverage unique biological mechanisms to combat various malignancies. This involves extensive research and clinical trials to validate the efficacy and safety of their therapeutic candidates, catering to patients with unmet medical needs.In its most recent fiscal year, 2015, TetraLogic Pharmaceuticals reported zero revenue, with an EBITDA of USD -44,803,033.The company plans to utilize the funds from its IPO to enhance research and development initiatives aimed at introducing new therapeutic candidates into clinical trials. TetraLogic is strategically targeting expansion into international markets, including Europe and Asia, by 2017, aiming to bring its innovative treatments to a broader patient population. This approach is aligned with their commitment to address critical health challenges in oncology.

## Funding rounds

- Series C, May 24, 2011, $6M — HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker Partners Management, Hatteras Venture Partners, Amgen Ventures, Clarus Ventures, Vertical Group, Nextech, Pfizer Venture Investments
- Series C, Oct 31, 2010, $23M — HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker Partners Management, Hatteras Venture Partners, Amgen Ventures, Clarus Ventures, Vertical Group, Pfizer Venture Investments
- Series C, Sep 27, 2010, $5M — Pfizer Venture Investments
- Series C, Aug 11, 2010, $13M — HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker Partners Management, Hatteras Venture Partners, Amgen Ventures, Clarus Ventures, Vertical Group, Pfizer Venture Investments
- Series B, Jun 12, 2006, $15M — HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker Partners Management, Amgen Ventures, Early Stage Partners, Vertical Group, Kammerer Associates
- Series A, Mar 1, 2004, $8M — HealthCare Ventures

## Investors

- HealthCare Ventures — Series A, Series B, Series C
- Latterell Venture Partners (https://capitalatlas.ai/funds/latterell-venture-partners) — Series B, Series C
- Novitas Capital (https://capitalatlas.ai/funds/novitas-capital) — Series B, Series C
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series B, Series C
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B, Series C
- Early Stage Partners (https://capitalatlas.ai/funds/early-stage-partners) — Series B
- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Series B, Series C
- Kammerer Associates (https://capitalatlas.ai/funds/kammerer-associates) — Series B
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series C
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series C